Market Overview:
The global seasonal affective disorder therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of SAD, rising awareness about SAD and its treatment options, and technological advancements in light therapy devices. The global seasonal affective disorder therapeutics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into light therapy (phototherapy), medication, and others. Light therapy (phototherapy) is further sub-segmented into conventional light therapy and dawn simulation/light box therapy. On the basis of application, the market is segmented into hospitals, clinics, and others.
Product Definition:
Seasonal Affective Disorder Therapeutics is a type of therapy used to treat Seasonal Affective Disorder (SAD), a mood disorder that occurs during specific times of the year, most often in winter. SAD is thought to be caused by changes in daylight hours and can result in symptoms such as depression, fatigue, and decreased interest in activities.
Light Therapy (Phototherapy):
Light therapy is a form of phototherapy used for the treatment of seasonal affective disorder (SAD) or winter depression. It involves exposure to specific wavelengths of light which are believed to be effective in triggering the body's natural healing process and relieving symptoms.
According to studies conducted by researchers at the University Of Wisconsin-Madison.
Medication:
Medication and its usage in seasonal affective disorder therapeutics market is a type of medicine used to reduce the symptoms of SAD. The most commonly prescribed medications are light boxes or bright lights therapy, anti-depressants, and MAO inhibitors (monoamine oxidase inhibitors).
Application Insights:
Based on application, the seasonal affective disorder therapeutics market is segmented into hospitals, clinics and other settings, and others. Hospitals held the largest share in 2017 owing to factors such as a high prevalence of patients suffering from SAD at hospitals. Furthermore, due to advanced healthcare facilities and treatments in major countries such as Germany and U.K., these disorders are being diagnosed more frequently which is boosting the overall hospital segment growth.
The clinics/others setting segment is expected to grow at a lucrative rate during the forecast period due to increasing awareness about SAD among various professionals including doctors, social workers etcetera who work in this sector or have personal experience with it. Moreover, there are no approved medications for use outside of clinical trials yet; therefore people suffering from Seasonal Affective Disorder (SAD) turn towards alternative treatment options such as light therapy or lifestyle modification for better results which further boosts this industry growth during its early stages of development across regions globally.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare infrastructure, high awareness levels coupled with relatively higher disposable income and better access to treatment are some of the factors responsible for its large share. Moreover, seasonal affective disorder is a recognized disease in this region which helps in generating revenue for light box and other devices used for treating SAD.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising consumer awareness regarding mental health along with increasing disposable income levels especially in developing countries such as India and China will drive growth during forecast years.
Growth Factors:
- Increasing awareness about Seasonal Affective Disorder (SAD) and its treatment options among people.
- Growing number of research studies on SAD that are helping to better understand the disorder and identify new treatment options.
- increasing demand for natural or non-pharmacological therapies for mental health conditions such as SAD.
- Development of novel, more effective, and safer treatments for SAD that are gaining approval from regulatory agencies worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Seasonal Affective Disorder Therapeutics Market Research Report
By Type
Light Therapy (Phototherapy), Medication, Others
By Application
Hospitals, Clinics, Others
By Companies
Allergan, Pfizer, Roche, Eli Lily, GlaxoSmithKline, Teva Pharmaceuticals, Bausch Health Companies, Mylan, Sanofi, Novartis, Johnson & Johnson, Koninklijke Philips, Beurer GmbH, Lucimed (Luminette)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Seasonal Affective Disorder Therapeutics Market Report Segments:
The global Seasonal Affective Disorder Therapeutics market is segmented on the basis of:
Types
Light Therapy (Phototherapy), Medication, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- Pfizer
- Roche
- Eli Lily
- GlaxoSmithKline
- Teva Pharmaceuticals
- Bausch Health Companies
- Mylan
- Sanofi
- Novartis
- Johnson & Johnson
- Koninklijke Philips
- Beurer GmbH
- Lucimed (Luminette)
Highlights of The Seasonal Affective Disorder Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Light Therapy (Phototherapy)
- Medication
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Seasonal Affective Disorder Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Seasonal Affective Disorder Therapeutics (SAD Therapy) is a treatment for Seasonal Affective Disorder. It is a combination of medication and therapy. The goal of SAD Therapy is to help people with Seasonal Affective Disorder feel better by improving their mood, energy levels, and sleep patterns.
Some of the major companies in the seasonal affective disorder therapeutics market are Allergan, Pfizer, Roche, Eli Lily, GlaxoSmithKline, Teva Pharmaceuticals, Bausch Health Companies, Mylan, Sanofi, Novartis, Johnson & Johnson, Koninklijke Philips, Beurer GmbH, Lucimed (Luminette).
The seasonal affective disorder therapeutics market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Seasonal Affective Disorder Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Seasonal Affective Disorder Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Seasonal Affective Disorder Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Seasonal Affective Disorder Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Seasonal Affective Disorder Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Seasonal Affective Disorder Therapeutics Market Size and Y-o-Y Growth
4.5.2 Seasonal Affective Disorder Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Seasonal Affective Disorder Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Seasonal Affective Disorder Therapeutics Market Size Forecast by Type
5.2.1 Light Therapy (Phototherapy)
5.2.2 Medication
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Seasonal Affective Disorder Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Seasonal Affective Disorder Therapeutics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Seasonal Affective Disorder Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Seasonal Affective Disorder Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Seasonal Affective Disorder Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Seasonal Affective Disorder Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Seasonal Affective Disorder Therapeutics Market Size Forecast by Type
9.6.1 Light Therapy (Phototherapy)
9.6.2 Medication
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Seasonal Affective Disorder Therapeutics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Seasonal Affective Disorder Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Seasonal Affective Disorder Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Seasonal Affective Disorder Therapeutics Market Size Forecast by Type
10.6.1 Light Therapy (Phototherapy)
10.6.2 Medication
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Seasonal Affective Disorder Therapeutics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Seasonal Affective Disorder Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Seasonal Affective Disorder Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Seasonal Affective Disorder Therapeutics Market Size Forecast by Type
11.6.1 Light Therapy (Phototherapy)
11.6.2 Medication
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Seasonal Affective Disorder Therapeutics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Seasonal Affective Disorder Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Seasonal Affective Disorder Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Seasonal Affective Disorder Therapeutics Market Size Forecast by Type
12.6.1 Light Therapy (Phototherapy)
12.6.2 Medication
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Seasonal Affective Disorder Therapeutics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Seasonal Affective Disorder Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Seasonal Affective Disorder Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Seasonal Affective Disorder Therapeutics Market Size Forecast by Type
13.6.1 Light Therapy (Phototherapy)
13.6.2 Medication
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Seasonal Affective Disorder Therapeutics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Seasonal Affective Disorder Therapeutics Market: Competitive Dashboard
14.2 Global Seasonal Affective Disorder Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan
14.3.2 Pfizer
14.3.3 Roche
14.3.4 Eli Lily
14.3.5 GlaxoSmithKline
14.3.6 Teva Pharmaceuticals
14.3.7 Bausch Health Companies
14.3.8 Mylan
14.3.9 Sanofi
14.3.10 Novartis
14.3.11 Johnson & Johnson
14.3.12 Koninklijke Philips
14.3.13 Beurer GmbH
14.3.14 Lucimed (Luminette)
